Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 plus Rituximab in Untreated Follicular Lymphoma
NCT00440388Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Oct 2006
- Primary completion
- Nov 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in follicular lymphoma (FL), sponsored by Ascenta Therapeutics. Started Oct 2006; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00440388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00440388.